Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

Alice P. Chen, Geraldine O’Sullivan Coyne, Pamela L. Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco, Zhongping Chen, Luiz Guilherme Darrigo, Marica Eoli, James R. Whittle, Yoshihiro Nishida, Rosa Lamarca, Randolph de la Rosa Rodríguez, Ayoade Adeyemi, I. Herrero, Nereida Llorente, Scott J. Diede, Eva Dombi, P. Wolkenstein, Alexander Lee, Angela Mastronuzzi, Angela Swampillai, Beniamin Bokhyan, Brian Van Tine, Carolina Barnett-Tapia, Cordula Matthies, Hans Shuhaiber, Jan Styczynski, Juan M. Sepulveda Sanchez, Laura Fertitta, Maëlla Severino-Freire, Maria D. D'Agostino, Marina Dorofeeva, Martin Schuhmann, Pinan Liu, Robert Nakayama, Rodrigo Perez Pereira, Silverio Perrotta, Viviane Sonaglio, Xinghua Gao, Yemima Berman, Yicheng Zhu, Yoshimasa Nobeyama